Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs.
Foot-and-mouth disease (FMD) is one of the most contagious and economically important diseases of cloven-hoofed livestock. Currently used inactivated FMD vaccines have short lived immunity besides risk of handling live virus. We studied recombinant FMD virus like particles (VLPs) encoded by FMDV type O/IND/R2/75 polyprotein genes expressed in Sf9 cells and adjuvanted with CpG or Poly I:C in inducing protective immune response in guinea pigs. Guinea pigs immunized with VLP + CpG vaccine had shown markedly higher cell mediated immunity (CMI) in comparison to the conventional vaccine group as evident from higher levels of IgG2 than IgG1. Although the humoral response was less in VLP + CpG compared to conventional vaccine, the lymphocyte stimulation index was more in VLP + CpG compared to conventional and VLP + Poly I:C vaccine groups. Finally the challenge experiments on 28 and 56 dpv had shown 75% protection in VLP + CpG immunized guinea pigs primary and boosted animals, while 50% and 62% protection in VLP + Poly I:C in primary and boosted animals, respectively. In conclusion, CpG adjuvant was found to be superior followed by ISA206 and Poly I:C in eliciting protection in VLP based FMD vaccines in guinea pigs.
Foot-and-Mouth Disease Vaccine Centre, Indian Veterinary Research Institute Campus, Hebbal, Bangalore, Karnataka 560 024, India.
Megolhubino
M
Terhuja
Foot-and-Mouth Disease Vaccine Centre, Indian Veterinary Research Institute Campus, Hebbal, Bangalore, Karnataka 560 024, India. Electronic address: drsaravana72@dr.com.
Paramasivam
P
Saravanan
Foot-and-Mouth Disease Vaccine Centre, Indian Veterinary Research Institute Campus, Hebbal, Bangalore, Karnataka 560 024, India.
Ramasamy Periyasamy
RP
Tamilselvan
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D036022:Capsid Proteins / Q000032:analysis / Q000276:immunology; D018899:CpG Islands / Q000276:immunology*; D004341:Drug Evaluation; D005260:Female; D005536:Foot-and-Mouth Disease / Q000517:prevention & control*; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D006168:Guinea Pigs; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008297:Male; D009500:Neutralization Tests; D017924:Nucleopolyhedroviruses; D011070:Poly I-C / Q000008:administration & dosage / Q000276:immunology*; D011994:Recombinant Proteins / Q000032:analysis / Q000276:immunology; D061987:Sf9 Cells; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000276:immunology*; D014776:Virus Cultivation
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D036022:Capsid Proteins; D007074:Immunoglobulin G; D011994:Recombinant Proteins; C442501:VP1 protein, Foot-and-mouth disease virus; C442459:VP2 protein, Foot-and-mouth disease virus; C442460:VP3 protein, Foot-and-mouth disease virus; D058425:Vaccines, Virus-Like Particle; D011070:Poly I-C
Baculovirus expression system; CMI response; Challenge studies; CpG; Poly I:C; Virus like particles (VLPs)